within Pharmacolibrary.Drugs.ATC.G;

model G04BE11
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.38,
    Cl             = 0.095,
    adminDuration  = 600,
    adminMass      = 0.1,
    adminCount     = 1,
    Vd             = 0.184,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.01883333333333333,
    Tlag           = 12.6
  );

  annotation(Documentation(
    info ="<html><body><p>Udenafil is a phosphodiesterase type 5 (PDE5) inhibitor used primarily for the treatment of erectile dysfunction. It exerts its effect by enhancing the nitric oxide–cGMP pathway, leading to smooth muscle relaxation and increased blood flow to the corpus cavernosum. Udenafil is approved for use in several countries, but is not approved by the FDA in the United States.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters obtained from healthy adult male volunteers following single oral administration.</p><h4>References</h4><ol><li><p>Choi, HK, et al., &amp; Shin, JG (2016). The Effect of Age on the Pharmacokinetics of Udenafil in Healthy Subjects. <i>Journal of clinical pharmacology</i> 56(11) 1372–1377. DOI:<a href=&quot;https://doi.org/10.1002/jcph.739&quot;>10.1002/jcph.739</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/27006150/&quot;>https://pubmed.ncbi.nlm.nih.gov/27006150</a></p></li><li><p>Kim, TE, et al., &amp; Yu, KS (2009). Effect of food on the pharmacokinetics of the oral phosphodiesterase 5 inhibitor udenafil for the treatment of erectile dysfunction. <i>British journal of clinical pharmacology</i> 68(1) 43–46. DOI:<a href=&quot;https://doi.org/10.1111/j.1365-2125.2009.03404.x&quot;>10.1111/j.1365-2125.2009.03404.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/19660002/&quot;>https://pubmed.ncbi.nlm.nih.gov/19660002</a></p></li><li><p>Lee, JH, et al., &amp; Baek, IH (2021). Gender differences and dose proportionality in the toxicokinetics of udenafil and its active metabolite following oral administration in rodents. <i>Toxicology and applied pharmacology</i> 410 115339–None. DOI:<a href=&quot;https://doi.org/10.1016/j.taap.2020.115339&quot;>10.1016/j.taap.2020.115339</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33221319/&quot;>https://pubmed.ncbi.nlm.nih.gov/33221319</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end G04BE11;
